Prediction of pharmacokinetic drug/drug interactions from in vitro data: Interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants

Drug Metabolism and Disposition

Volumn 28, Issue 2, 2000, Pages 161-168

  Kohl, Christopher ^a,b   Steinkellner, Michael ^a  

^a Nycomed Holdings AS   (Austria)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; LORNOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; TENOXICAM; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; PREDICTION; PRIORITY JOURNAL;

EID: 0033956664     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-9556(24)15123-9     Document Type: Article

References (40)

1. Balfour JA, Fitton A and Barradell LB (1996) Lornoxicam: A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 51:639-657.
2. Ball SE, Scatina JA, Sisenwine SF and Fisher GL (1995) The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem Toxicol 18:1-28.
3. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
4. Bonnabry P, Leemann T and Dayer P (1996) Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 49:305-308.
5. Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB and Rowland M (1994) Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37:563-569.
6. 1-acid glycoprotein chiral stationary phase. J Chromatogr 644:315-320.
7. Eichler HG, Jung M, Kyrle PA, Rotter M and Kron A (1992) Absence of interaction between tenoxicam and warfarin. Ear J Clin Pharmacol 42:227-229.
8. Fuhr U, Weiss M, Kroemer HK, Neugebauer G, Rameis H, Weber W and Woodcock BG (1996) Systematic screening for pharmacokinetic interactions during drug development. Int J Clin Pharmacol Ther 34:139-151.
9. Gill TS, Hopkins KJ and Rowland M (1988) Stereospecific assay of nicoumalone: Application to pharmacokinetic studies in man. Br J Clin Pharmacol 25:591-598.
10. Harder S and Thürmann P (1996) Clinically important drug interactions with anticoagulants. Clin Pharmacokinet 30:416-444.
11. He M, Kunze KL and Trager WF (1995) Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. Drug Metab Dispos 23:659-663.
12. Hermans JJR and Thijssen HHW (1993) Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 110:482-490.
13. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
14. Jones JP, He M, Trager WF and Rettie AE (1996) Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P450 2C9. Drug Metab Dispos 24:1-6.
15. Kitteringham NR, Büstgens L, Brundert E, Mineshita S and Ohnhaus EE (1984) The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. Eur J Clin Pharmacol 26:65-70.
16. Kunze KL, Wienkers LC, Thummel KE and Trager WF (1996) Warfarin-fluconazole. 1: Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab Dispos 24:414-421.
17. Lake BG (1987) Preparation and characterisation of microsomal fractions for studies on xenobiotic metabolism, in Biochemical Toxicology (Snell K and Mullock B eds) pp 183-213, IRL Press, Oxford.
18. Leatherbarrow RJ (1992) GraFit Version 3.0, Erithacus Software Ltd., Staines, UK.
19. Lin JH and Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
20. Lowry OH, Roseborough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Masche UP, Rentsch KM, von Felten A, Meier PJ and Fattinger KE (1999a) No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol 54:865-868.
22. Masche UP, Rentsch KM, von Felten A, Meier PJ and Fattinger KE (1999b) Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol 54:857-864.
23. Miners JO and Birkett DJ (1998) Cytochrome P450 2C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
24. Miners JO, Rees DLP, Valente L, Veronese ME and Birkett DJ (1995) Human hepatic cytochrome P-450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 272:1076-1081.
25. Nygaard G, Hudson M, Mazure G, Anthony A, Dhillon AP, Pounder RE and Wakefield AJ (1995) Procoagulant and prothrombotic responses of human endothelium to indomethacin and endotoxin in vitro. Relevance to non-steroidal anti-inflammatory drug enteropathy. Scand J Gastroenterol 30:25-32.
26. Obach RS (1997) Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
27. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
28. Ravic M, Johnston A, Turner P and Ferber HP (1990) A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol 9:413-414.
29. Ring BJ, Binkley SN, Roskos L and Wrighton SA (1995) Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 275:1131-1135.
30. Ring BJ, Binkley SN, Vandenbranden M and Wrighton SA (1996) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41:181-186.
31. Skjodt NM and Davies NM (1998) Clinical pharmacokinetics of lornoxicam. Clin Pharmacokinet 34:421-428.
32. Toon S, Heimark LD, Trager WF and O'Reilly RA (1985) Metabolic fate of phenprocoumon in humans. J Pharm Sci 74:1037-1040.
33. Tsai RS, Carrupt PA, El Tayar N, Giroud Y, Andrade P, Testa B, Breé F and Tillement JP (1993) Physicochemical and structural properties of non-steroidal anti-inflammatory oxicams. Helv Chim Acta 76:842-854.
34. Verbeeck RK and Wallace SM (1994) Non-steroidal anti-inflammatory drugs: Restrictive or non-restrictive clearance? Arzneim-Forsch 44:683-685.
35. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS and Shader RI (1994) In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222-1227.
36. von Moltke LL, Greenblalt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 27:370-379.
37. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-47.
38. Woolf TF and Radulovic LL (1989) Oxicams: Metabolic disposition in man and animals. Drug Metab Rev 21:255-276.
39. Wrighton SA and Ring BJ (1999) Predicting drug interactions and pharmacokinetic variability with in vitro methods: The olanzapine experience. Drug Metab Rev 31:15-28.
40. Zhao J, Leemann T and Dayer P (1992) In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sci 51:575-581.